A Multicenter, Randomized, Open-Label,Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer

Condition:   Differentiated Thyroid Cancer
Interventions:   Drug: Donafenib 200mg;   Drug: Donafenib 300mg
Sponsor:   Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Not yet recruiting - verified August 2016

from #ORL via xlomafota13 on Inoreader http://ift.tt/2bcp43U
via IFTTT